This population-based cohort study describes the long-term outcome and relapse pattern in a real-world cohort covering all patients with early stages of HER2-positive breast cancer, both those treated with trastuzumab in the adjuvant setting and those who did not undergo such treatment, under a period of eight years. The gene discussed is ERBB2; the disease is breast carcinoma.